TEVA 2203 Pill — WHITE ROUND, 8mm — Metoclopramide

No photo available

Imprint	TEVA / 2203
Colour	WHITE
Shape	ROUND
Size	8
Strength	METOCLOPRAMIDE HYDROCHLORIDE 10 mg
Dosage form	Tablet
Manufacturer	Denton Pharma, Inc. DBA Northwind Pharmaceuticals
NDC	70934-384
Schedule	—
Availability	—
Ingredients	METOCLOPRAMIDE HYDROCHLORIDE[METOCLOPRAMIDE]

What does this imprint mean?

The imprint "TEVA 2203" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Metoclopramide

Uses and warnings

BOXED WARNING: TARDIVE DYSKINESIA - Metoclopramide "can cause tardive dyskinesia (TD), a potentially irreversible, serious movement disorder." Risk increases "with duration of treatment and total cumulative dosage." The label states "metoclopramide is contraindicated in patients with a history of TD," limits treatment to a maximum of 12 weeks for GERD, and instructs to "immediately discontinue metoclopramide in patients who develop signs or symptoms of TD." Other major warnings include neuroleptic malignant syndrome, depression with suicidal ideation, and hypertensive crisis in patients with pheochromocytoma.

Indicated for "treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux disease in adults who fail to respond to conventional therapy" and for "relief of symptoms associated with acute and recurrent diabetic gastroparesis." Not recommended in pediatric patients because of increased risk of tardive dyskinesia, other extrapyramidal effects, and methemoglobinemia in neonates.

Read the full drug profile →